Recent Company News

• 08:50 AM ET Mar 20, 2026
  

  StreetAccount Sector Summary - Healthcare Pre-Market

• 06:15 AM ET Mar 20, 2026
  

  Adlai Nortye initiated outperform at Leerink Partners ($7.36, 0.00)

• 08:50 AM ET Mar 10, 2026
  

  Adlai Nortye files $600M Class A ordinary shares shelf - F-3 ($8.79, 0.00)

• 09:38 AM ET Feb 13, 2026
  

  Adlai Nortye upgraded to buy from neutral at HC Wainwright ($9.77, +0.12)

• 04:05 AM ET Feb 12, 2026
  

  Adlai Nortye doses first patient in US for phase 1 trial of AN9025 for advanced or metastatic solid tumors harboring RAS mutations ($9.29, 0.00)

• 09:22 AM ET Feb 03, 2026
  

  StreetAccount Summary - US Pre-market trading update

• 09:22 AM ET Feb 03, 2026
  

  StreetAccount Summary - US Syndicate recap for 03-Feb

• 08:41 AM ET Feb 03, 2026
  

  StreetAccount Summary - US Initial Syndicate recap for 03-Feb

• 08:28 AM ET Feb 03, 2026
  

  StreetAccount Summary - US Pre-market trading

• 07:08 AM ET Feb 03, 2026
  

  Adlai Nortye announces $140.0M private placement of ~21.5M ADSs priced at $6.50/ADS ($9.27, 0.00)